Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Acumen Pharmaceuticals Inc (ABOS)

84 + Investors. Track Smart Money conviction in ABOS. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +14
Streak
2Q ▲
Buyers last Q
72%

Smart Money Signals — ABOS

Based on 84 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added ABOS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
84 hedge funds hold ABOS right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +4% more funds vs a year ago

fund count last 6Q
+3 new funds entered over the past year (+4% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 72% buying

52 buying20 selling
Last quarter: 52 funds were net buyers (21 opened a brand new position + 31 added to an existing one). Only 20 were sellers (13 trimmed + 7 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+9 vs last Q)

new funds entering per quarter
Funds opening a new ABOS position: 16 → 13 → 12 → 21. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

49% of holders stayed for 2+ years

■ 49% conviction (2yr+) ■ 26% medium ■ 25% new
41 out of 84 hedge funds have held ABOS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📈

Growing discovery — still being found

12 → 16 → 13 → 12 → 21 new funds/Q
New funds entering each quarter: 16 → 13 → 12 → 21. A growing number of institutions are discovering ABOS each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 61% veterans vs 27% newcomers

■ 61% veterans ■ 11% 1-2yr ■ 27% new
Entry-cohort mix of 88 holders: 54 (61%) are 2+ year veterans, 10 entered 1–2 years ago, and 24 (27%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 14% AUM from top-100

14% from top-100 AUM funds
23 of 83 holders rank in the top 100 by AUM, but together hold only 14% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ABOS

In 2026 Q1, 52 hedge funds were net buyers of ABOS (21 opened a new position, 31 added to an existing one), while 20 reduced or exited (13 trimmed, 7 sold completely) — a 72% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. Net fund flow last quarter: +14 funds (more new holders than closures). Total institutional holders: 84.

Hedge Fund Ownership: ABOS

How many hedge funds hold ABOS — quarterly history vs. share price
Quarterly hedge fund ownership of ABOS vs. share price

Market Analysis: ABOS

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ABOS

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Acumen Pharmaceuticals Inc (ABOS) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ABOS has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 89d ago
ABOS
nan%
XLV
+9.2%

ABOS outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 44d ago
ABOS
nan%
XLV
+10.3%

Since the filing became public, ABOS outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

8 top-rated funds 0 high-conviction
Consensus
4.1
/ 10
breadth
×
Elite
0.3
/ 10
conviction
Hedge Fund Positioning: ABOS
84 + Investors

Track Smart Money conviction in ABOS. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 84 70 20.0%
13F Shares 47M 36M 30.53%
Total Value $108M $75M 43.01%
New Positions 21 12 +9
Increased Positions 31 13 +18
Closed Positions 7 11 -4
Reduced Positions 12 21 -9
Total Calls 2 1 100.0%
Total Puts 3 0 100%
PUT/CALL Ratio 1.5 0.0 Bearish

Statistics: ABOS

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

84 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ABOS. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ABOS holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Sands Capital Alternatives, LLC 2.08% 3,720,105 $8.8M
2 Ra Capital Management, L.P. 0.52% 20,992,669 $49.5M
3 Knollwood Investment Advisory, LLC 0.39% 1,628,510 $3.8M
4 ADAR1 Capital Management, LLC 0.30% 2,156,334 $5.1M
5 Ikarian Capital, LLC 0.20% 1,053,797 $2.5M
6 Verdad Advisers, LP 0.10% 37,278 $88K
7 Rangeley Capital, LLC 0.08% 35,000 $83K
8 Laurion Capital Management LP 0.05% 525,444 $1.2M
9 Intrepid Financial Planning Group LLC 0.03% 30,150 $71K
10 Catalyst Financial Partners LLC 0.02% 89,699 $212K
11 Catalyst Funds Management Pty Ltd 0.02% 45,600 $108K
12 Alyeska Investment Group, L.P. 0.02% 2,454,754 $5.8M
13 PFG Investments, LLC 0.01% 80,850 $191K
14 Axq Capital, LP 0.01% 28,487 $67K
15 Bridgeway Capital Management, LLC 0.01% 176,171 $416K
16 Boothbay Fund Management, LLC 0.01% 273,012 $644K
17 Pathstone Holdings, LLC 0.01% 859,110 $2.0M
18 Hudson Bay Capital Management LP 0.01% 968,940 $2.3M
19 Factor Wealth Management LTD 0.01% 16,500 $39K
20 Pinnacle Wealth Management Advisory Group, LLC 0.00% 18,020 $43K
21 Prospera Financial Services Inc 0.00% 50,000 $118K
22 Renaissance Technologies LLC 0.00% 473,946 $1.1M
23 Two Sigma Advisers, LP 0.00% 421,800 $890K
24 Franklin Resources Inc 0.00% 2,305,096 $5.4M
25 Two Sigma Investments, LP 0.00% 530,812 $1.3M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Acumen Pharmaceuticals Inc (ABOS)

What does the Smart Money Trend signal show for ABOS?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added ABOS than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ABOS?

More buyers than sellers — 72% buying: Last quarter: 52 funds were net buyers (21 opened a brand new position + 31 added to an existing one). Only 20 were sellers (13 trimmed + 7 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for ABOS holders?

Smaller funds dominant — 14% AUM from top-100: 23 of 83 holders rank in the top 100 by AUM, but together hold only 14% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held ABOS?

49% of holders stayed for 2+ years: 41 out of 84 hedge funds have held ABOS for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Acumen Pharmaceuticals Inc (ABOS) following the 2026 Q1 hedge fund 13F filings?

As of today, ABOS has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +10.3% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), ABOS has gained nan% vs +9.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →